Want to join the conversation?
As a result of the NorMedix transaction, $SRDX lifted FY16 revenue guidance to range of $62-66MM from previous forecast range of $60-64MM. For 2016, $SRDX lowered its EPS outlook to range of $0.30-0.35 from prior forecast of $0.38-0.43. The transaction is not expected to impact non-GAAP earnings guidance of $0.66-0.75 per share.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?